Liver transplantation in patients with ACLF and multiple organ failure: Time for priority after initial stabilization
EASL LiverTree™, Faouzi Saliba, 234534
Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort
EASL LiverTree™, Naveed Janjua, 234535
Multi-organ assessment of compensated cirrhosis patients using quantitative magnetic resonance imaging
EASL LiverTree™, Indra Guha, 234536
Chimeric liver transplantation reveals interspecific graft remodelling
EASL LiverTree™, Christian Toso, 234537
Ex vivo liver resection and autotransplantation as alternative to allotransplantation for end-stage hepatic alveolar echinococcosis
EASL LiverTree™, Hao Wen, 234538
Liver transplantation in patients with multiple organ failures: Feasibility and outcomes
EASL LiverTree™, Paul Joseph Thuluvath, 234539
Exercise in cirrhosis: Translating evidence and experience to practice
EASL LiverTree™, Puneeta Tandon, 234550
Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection
EASL LiverTree™, Johannes Vermehren, 234551
The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat
EASL LiverTree™, Alison D. Marshall, 234552
The role of Kupffer cells in hepatic iron and lipid metabolism
EASL LiverTree™, Martin Guilliams, 234553
Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis
EASL LiverTree™, Ewan H Forrest, 234554
Reply to: “Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis”
EASL LiverTree™, Thomas Sersté, 234555
Ex vivo liver resection and autotransplantation: An emerging option in selected indications
EASL LiverTree™, Tomoaki Kato, 256697
Liver transplantation in patients with ACLF and multiple organ failure: Time for priority after initial stabilization
EASL LiverTree™, Faouzi Saliba, 256698
Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort
EASL LiverTree™, Naveed Janjua, 256699
Multi-organ assessment of compensated cirrhosis patients using quantitative magnetic resonance imaging
EASL LiverTree™, Indra Guha, 256700
Chimeric liver transplantation reveals interspecific graft remodelling
EASL LiverTree™, Christian Toso, 256701
Ex vivo liver resection and autotransplantation as alternative to allotransplantation for end-stage hepatic alveolar echinococcosis
EASL LiverTree™, Hao Wen, 256702
An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers
EASL LiverTree™, Giulio Marchesini, 256713
Exercise in cirrhosis: Translating evidence and experience to practice
EASL LiverTree™, Puneeta Tandon, 256714
Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection
EASL LiverTree™, Johannes Vermehren, 256715
The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat
EASL LiverTree™, Alison D. Marshall, 256716
The role of Kupffer cells in hepatic iron and lipid metabolism
EASL LiverTree™, Martin Guilliams, 256717
Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis
EASL LiverTree™, Ewan H Forrest, 256718
From the Editor’s Desk…
EASL LiverTree™, Richard Moreau, 234485
JHEP at a glance (October 2018)
EASL LiverTree™, Journal of Hepatology, 234486
Viral hepatitis: “E” is for equitable elimination
EASL LiverTree™, Jeffrey Lazarus, 234487
Predicting treatment eligibility for hepatitis B in low income regions: Can treatment scores without HBV DNA testing serve the purpose?
EASL LiverTree™, Geoffrey Dusheiko, 234488
A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over!
EASL LiverTree™, Georges-Philippe PAGEAUX, 234489
Ruling out esophageal varices in NAFLD cirrhosis: Can we do without endoscopy?
EASL LiverTree™, Roberto de Franchis, 234490
The multi-dimensional role of intestinal HIFs in liver pathobiology
EASL LiverTree™, Wajahat Mehal, 234491
Predicting the future burden of NAFLD and NASH
EASL LiverTree™, Jacob George, 234492
Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa
EASL LiverTree™, Maud Lemoine, 234493
Assessing the cost-effectiveness of hepatitis C screening strategies in France
EASL LiverTree™, Sylvie Deuffic-Burban, 234494
Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B
EASL LiverTree™, Vincent Wong, 234495
The intensive care unit course and outcome in acute-on-chronic liver failure are comparable to other populations
EASL LiverTree™, Schalk van der Merwe, 234496
Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry
EASL LiverTree™, Luca Saverio Belli, 234497
Karnofsky performance status before and after liver transplantation predicts graft and patient survival
EASL LiverTree™, Paul Joseph Thuluvath, 234498
Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib
EASL LiverTree™, Stephanie Ma, 234499
Mutational landscape of a chemically-induced mouse model of liver cancer
EASL LiverTree™, Duncan T. Odom, 234500
hiPSC hepatocyte model demonstrates the role of unfolded protein response and inflammatory networks in α-antitrypsin deficiency
EASL LiverTree™, Ludovic Vallier, 234501
Long noncoding RNA lncHand2 promotes liver repopulation via c-Met signaling
EASL LiverTree™, Zusen Fan, 234502
Family occurrence of autoimmune hepatitis: A Danish nationwide registry-based cohort study
EASL LiverTree™, Lisbet Grønbæk, 234503
Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis
EASL LiverTree™, Salvatore Petta, 234504
Intestinal HIF-1α deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction
EASL LiverTree™, Wenke Feng, 234505
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
EASL LiverTree™, Homie Razavi, 234506
Urea cycle dysregulation in non-alcoholic fatty liver disease
EASL LiverTree™, Karen Louise Thomsen, 234507
New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings
EASL LiverTree™, Stephane Chevaliez, 234508
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease
EASL LiverTree™, Béatrice Bailly-Maitre, 234509
Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications
EASL LiverTree™, Guruprasad Aithal, 234510
Cirrhotic cardiomyopathy
EASL LiverTree™, Samuel Lee, 234511
Allogeneic haematopoietic stem cell transplantation eliminates alloreactive inhibitory antibodies after liver transplantation for bile salt export pump deficiency
EASL LiverTree™, Verena Keitel, 234512
Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain
EASL LiverTree™, Marina Berenguer, 234513
Persistence of NS5B-S282T, a sofosbuvir resistance-associated substitution, in a HIV/HCV-coinfected MSM with risk of onward transmission
EASL LiverTree™, Astrid Newsum, 234514
Association between cirrhosis and hip fracture in older people in a population-based cohort study
EASL LiverTree™, Kuan-Fu Liao, 234515
NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis
EASL LiverTree™, Edoardo G. Giannini, 234516
Reply to: “NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis”
EASL LiverTree™, Paul Joseph Thuluvath, 234517
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis
EASL LiverTree™, Astrid Marot, 234518
Mortality due to immunotherapy related hepatitis
EASL LiverTree™, Siddharth Sood, 234519
Reply to: “Mortality due to immunotherapy related hepatitis”
EASL LiverTree™, Didier Samuel, 234520
Immunotolerant children with chronic hepatitis B – To treat or not – The dilemma continues
EASL LiverTree™, Seema Alam, 234521
Reply to: “Immunotolerant children with chronic hepatitis B – To treat or not – The dilemma continues”
EASL LiverTree™, Pan Zhao, 234522
Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany
EASL LiverTree™, Kerstin Herzer, 234523
Clinical use of dendritic cell-derived exosomes for hepatocellular carcinoma immunotherapy: How far we are?
EASL LiverTree™, Yuan Li, 234524
Corrigendum to “From the Editor’s Desk August 2018” [J Hepatol 69 (2018) 265–268]
EASL LiverTree™, Richard Moreau, 234525
Corrigendum to “A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer” [J Hepatol 69 (2018) 385–395]
EASL LiverTree™, Scott L. Friedman, 234526
Corrigendum to “Recipient characteristics and morbidity and mortality after liver transplantation” [J hepatol 69 (2018) 43–50]
EASL LiverTree™, Sumeet Asrani, 234527
Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008]
EASL LiverTree™, Josep M. Llovet, 234528
Meeting Close
EASL LiverTree™, Elisabetta BUGIANESI, 227298
Consensus Statement V: Which patients with NASH should be considered for transplantation? How best to assess risk in this cohort? What is the role of bariatric surgery in the peri-transplant setting
EASL LiverTree™, Session Speakers, 231720
Transplantation for NAFLD - outcomes and complications
EASL LiverTree™, Paolo Muiesan, 227295
Clinical Case V - Patient with decompensated NASH
EASL LiverTree™, Patrizia Burra, 227293
Assessment of NIS4 clinicalutility for identification of patients with active NASH (NAS≥4) and significant fibrosis (F≥2) in patients at risk of NASH
EASL LiverTree™, Arun Sanyal, 226719
The TM6SF2-E167K variant promotes liver cancer through hepatic lipid accumulation, tissue damage and inflammation
EASL LiverTree™, Emma Scott, 226721
Treatment with Obeticholic Acid in Patients with NASH Does Not Show Increased Markers of Liver Toxicity Based on Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH)
EASL LiverTree™, David Shapiro, 226722
NAFLD in newly diagnosed Type 2 Diabetes: prevalence and risk factors from a South Asian population
EASL LiverTree™, Fatima Sharif, 226723
N-3 polyunsaturated fattyacids in NAFLD (a double-blind randomised placebo-controled study)
EASL LiverTree™, Vaclav Smid, 226724
B-lymphocytes contribute to the evolution of nonalcoholicfatty liver disease (NAFLD)
EASL LiverTree™, Salvatore Sutti, 226725
DNA damage and repair in Non-Alcoholic Steatohepatitis (NASH)
EASL LiverTree™, Janusz Szemraj, 226726
Inhibition of DGAT2 improves hepatic steatosis, inflammation and cardiovascular risk factors in the LDLr-/-.Leiden mouse.
EASL LiverTree™, Gregory Tesz, 226727
Dietary cholesterol mitigates liver bile acid toxicity by activation of phase 1 regenerative response
EASL LiverTree™, Oren Tirosh, 226728
Transcriptomic profiles of transplanted livers that developed NAFLD
EASL LiverTree™, Pavel Trunecka, 226729
Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH model
EASL LiverTree™, Robert Walczak, 226730
The influence of tumour necrosis factor on early fibrogenesis in a diet-induced NAFLD mouse model - a histological description
EASL LiverTree™, Christine Yee, 226731
Autoimmunity and NAFLD: Clinical Characteristics and Long-Term Outcomes of Patients with Antinuclear Antibody Positivity. A Longitudinal Multicentric European Study.
EASL LiverTree™, Ramy Younes, 226732
Consensus Statement IV: When do we need pharmacological interventions? What are the treatment objectives?
EASL LiverTree™, Session Speakers, 231719
Assessing cost effectiveness of pharmacotherapy - how will it work in NAFLD?
EASL LiverTree™, Martin Harker, 227285
Sequential or combination therapy - what challenges does this pose?
EASL LiverTree™, Aditi Saxena, 227284
Licensing end-points - update from AASLD/EASL end-points meeting 2018
EASL LiverTree™, Arun Sanyal, 227283
Anti-fibrotic agents
EASL LiverTree™, Fabio Marra, 227274
Mechanisms and pathways of hepatocyte cell-death in steatohepatitis
EASL LiverTree™, Jérémie Gautheron, 227273
Insights on Lipotoxicity from Clinical Trials: Targeting Lipogenesis
EASL LiverTree™, Chuhan Chung, 227272
Association between metabolic risk factors and histological characteristics in non-cirrhotic NAFLD
EASL LiverTree™, Eva Kalliga, 226705
Modelling NASH for drug discovery using 3D liver microtissues
EASL LiverTree™, Radina Kostadinova, 226706
High fat high sucrose intake underlies the progression of simple steatosis to nonalcoholic steatohepatitis
EASL LiverTree™, Fedra Luciano-Mateo, 226707
Nicotinamide, a surtuin modifier, ameliorates hepatic steatosis by alternating bile acid metabolism in the liver but not in the gut and microbiota.
EASL LiverTree™, Makoto Nakamuta, 226712
In overweight patients with non-alcoholic fatty liver disease Saroglitazar is able to improve transaminases but not liver stiffness measurement and controlled attenuation parameter unless accompanied by weight reduction
EASL LiverTree™, Prateek Padole, 226714
Influence of Hypothyroidism on Insulin Resistance and Adipokine Profile in Patients with Nonalcoholic Fatty Liver Disease
EASL LiverTree™, Vasyl PRYSYAZHNYUK, 226715
RNase MCPIP1 regulates hepatic PPAR gamma via TXNIP/PGC 1-alpha pathway
EASL LiverTree™, Natalia PYDYN, 226716
Insulin secretion is directly related to NASH, fibrogenesis and fibrosis in Non-diabetic patients with Non-Alcoholic Fatty Liver Disease
EASL LiverTree™, Chiara Rosso, 226717

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings